Semaxanib
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
Semaxanib (
experimental stage drug, not licensed for use on human patients outside clinical trials
.
Semaxanib is a potent and selective synthetic antiangiogenic potential.[citation needed
]
Research
In February 2002, Pharmacia, the then-parent of Sugen, prematurely ended phase III clinical trials of semaxinib in the treatment of advanced colorectal cancer due to discouraging results.[2] Other studies, at earlier phases, have since been conducted.[3][4] However, due to the prospect of next-generation tyrosine kinase inhibitors and the inefficacy of semaxanib in clinic trials, further development of the drug has been discontinued.[5] A related compound, SU11248 (sunitinib), was further developed by Sugen and subsequently by Pfizer, and received FDA approval for treatment of renal carcinoma in January 2006.[6]
When combined with chronic exposure to
hypoxia, SU5416 induces severe pulmonary hypertension in mice and rats. This property has been exploited to develop a series of useful, though controversial, rodent models of pulmonary arterial hypertension, the first and best characterized being the Sugen/Hypoxia (SuHx) mouse model.[7][8]
References
- KiB)
- ^ "Pharmacia Announces Closing of SU5416 (semaxanib) Clinical Trials" (Press release). February 8, 2002. Retrieved 2007-03-20.
- PMID 16222321.
- S2CID 26566099.
- PMID 16449240.
- ^ "FDA approves new treatment for gastrointestinal and kidney cancer". U.S. Food and Drug Administration (FDA). 2006. Archived from the original on 3 February 2006.
- PMID 25610598.
- PMID 34631012.